Israel’s Aidoc, which provides artificial intelligence tools for radiologists, said the U.S. Food and Drug Administration cleared the company’s product for triage of cervical spine fractures.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
There are some phrases which have become commonplace in pharma over the past few years. First, that data is the ‘new lifeblood’, able to make better, faster, more reliable decisions. But how many of us have really realized this benefit in a noticeable manner?
LabTwin’s AI-powered Digital Assistant Now Talks Back and Connects Data Sources in the Lab with New Open API
LabTwin GmbH, the world’s first voice and AI-powered digital lab assistant, announced the company’s new open API that will connect scientists with data sources both inside and outside of the lab.
Award-Winning Workplace Uses Complex Algorithms to Create Personalized Company Yearbooks for Every Employee
Klick Inc., a six-time-and-counting 2019 Best Workplace award recipient, is rewriting the book on employee engagement.
Israel’s Zebra Medical Vision received approval from the U.S. Food and Drug Administration for the company’s artificial intelligence-based chest X-ray triage product.
I got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.
Artificial intelligence (AI) is increasingly seen as a tool in biopharma and life sciences to improve drug development. There is a bit of a resource lag because AI is expensive. For example, Google/Alphabet owns an AI laboratory called DeepMind. Google acquired DeepMind in 2014 for a reported $650 million. Google, as one of the largest corporations on Earth, is very interested in the use of AI and health care.
Gilead Sciences Inc. will partner with privately held insitro to develop therapies for a fatty liver disease called NASH.
Bristol-Myers Squibb inked a multi-year strategic agreement with Concerto HealthAI, which focuses on oncology-specific Real-World Data and advanced AI for Real-World Evidence generation.
U.K.-based Exscientia signed a three-year artificial intelligence (AI)-based drug discovery collaboration with Celgene.